Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
GEO DataSets Gene Profile neighbors Chromosome neighbors
MTO1 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
GEO DataSets Gene Profile neighbors Chromosome neighbors Homologene neighbors
MASP1 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
GEO DataSets Profile neighbors
ITGA9 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
MLC1 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
MIR3682 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
MBP - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
IDUA - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
SLC2A4 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
HCN1 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
PRKACB - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
PBLD - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
ZNF331 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
FPR2 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
FARS2 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
THRSP - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
CD22 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on